Hepatorenal syndrome (HRS) is a serious complication of advanced liver disease, characterized by kidney dysfunction related to circulatory changes caused by cirrhosis and associated with significant mortality. Although HRS is considered a diagnosis of exclusion, the diagnostic criteria for HRS have recently been revised to reflect differences in AKI in patients with cirrhosis. Additionally, although treatment options are limited for the treatment of HRS, terlipressin has been recently approved for use in the United States for this indication. The purpose of this session is to provide updates in the diagnostic criteria for HRS and management of HRS including vasoactive therapy and use of albumin. 

Faculty

Moderator: Stephanie Bass, Pharm.D., FCCP, BCCCP, BCPS Medical ICU Clinical Pharmacist Cleveland Clinic Cleveland, Ohio   View Biography